Compare BridgeBio Pharma Inc (BBIO) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs HubSpot Inc — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while HubSpot Inc trades at $216.5 (market cap $11.00B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | HUBS | |
|---|---|---|
Market Cap | $16.36B | $11.00B |
Sector | Health | Technology |
52-Week High | $90.17 | $522.97 |
52-Week Low | $47.29 | $170.39 |
Enterprise Value | $18.14B | $9.89B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
